The estimated Net Worth of Pamela Vig is at least $5.27 Million dollars as of 24 June 2024. Ms. Vig owns over 30,559 units of Mirum Pharmaceuticals Inc stock worth over $2,429,313 and over the last 5 years she sold MIRM stock worth over $162,518. In addition, she makes $2,681,960 as Chief Scientific Officer at Mirum Pharmaceuticals Inc.
Pamela has made over 7 trades of the Mirum Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 30,559 units of MIRM stock worth $89,843 on 24 June 2024.
The largest trade she's ever made was exercising 30,559 units of Mirum Pharmaceuticals Inc stock on 24 June 2024 worth over $89,843. On average, Pamela trades about 1,948 units every 88 days since 2019. As of 24 June 2024 she still owns at least 57,965 units of Mirum Pharmaceuticals Inc stock.
You can see the complete history of Ms. Vig stock trades at the bottom of the page.
Pamela Vig serves as Chief Scientific Officer of the Company. Dr. Vig served as Chief Scientific Officer and clinical lead at Flashlight from November 2017. Dr. Vig served as Vice President, Clinical Research and Discovery at Tobira from July 2015 until its acquisition in November 2016 by Allergan. As part of the Tobira acquisition, she joined Allergan as Associate Vice President, Clinical Research and Development, a position she held until November 2017. Prior to joining Tobira, Dr. Vig served as Vice President, Clinical Research for Presidio Pharmaceuticals (“Presidio”), from January 2010 to July 2015. At Presidio, Dr. Vig was responsible for optimizing the design and conduct of the company’s clinical trial programs. Dr. Vig also previously served as Director, Global Medical Affairs, at Johnson & Johnson in London, United Kingdom, where she was responsible for the strategy and optimization of late-stage development and commercialization of HCV and HIV compounds. She has also held various positions at Idenix Pharmaceuticals and Gilead Sciences. Dr. Vig received a M.Phil. and a Ph.D. from Imperial College London from the Department of Hepatology in Investigative Science.
As the Chief Scientific Officer of Mirum Pharmaceuticals Inc, the total compensation of Pamela Vig at Mirum Pharmaceuticals Inc is $2,681,960. There are 2 executives at Mirum Pharmaceuticals Inc getting paid more, with Christopher Peetz having the highest compensation of $6,235,180.
Pamela Vig is 49, she's been the Chief Scientific Officer of Mirum Pharmaceuticals Inc since 2018. There are 11 older and 7 younger executives at Mirum Pharmaceuticals Inc. The oldest executive at Mirum Pharmaceuticals Inc is Michael Grey, 67, who is the Chairman of the Board.
Pamela's mailing address filed with the SEC is C/O MIRUM PHARMACEUTICALS, INC., 989 E HILLSDALE BLVD., SUITE 300, FOSTER CITY, CA, 94404.
Over the last 5 years, insiders at Mirum Pharmaceuticals Inc have traded over $10,912,565 worth of Mirum Pharmaceuticals Inc stock and bought 7,735,045 units worth $117,972,829 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Mirum Pharmaceuticals Inc executives and independent directors trade stock every 24 days with the average trade being worth of $4,538,937. The most recent stock trade was executed by Patrick J Heron on 6 September 2024, trading 230 units of MIRM stock currently worth $9,563.
mirum pharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. its lead product candidate is maralixibat, an investigational oral drug that is in phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of alagille syndrome and biliary atresia disease. the company is also develops volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. mirum pharmaceuticals, inc. was founded in 2018 and is headquartered in foster city, california.
Mirum Pharmaceuticals Inc executives and other stock owners filed with the SEC include: